Drugs / aKLmRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07544420 | May → Nov 2026 expected | — | Klothea Bio Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aKLmRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07544420 ↗ |
| Modality | Messenger RNA (mRNA) | “Alpha Klotho mRNA (aKLmRNA)” NCT07544420 ↗ |
| Route | Intravenous | “aKLmRNA via i.v.” NCT07544420 ↗ |